Status:
COMPLETED
Dose Response to Recombinant Factor VIIa When Administered for Bleed
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Healthy
Eligibility:
MALE
18-60 years
Phase:
PHASE1
Brief Summary
This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for blee...
Eligibility Criteria
Inclusion
- Ages Eligible for Study: 18 Years - 60 Years
Exclusion
- \- -
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00104455
Start Date
June 1 2004
End Date
November 1 2004
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Overland Park, Kansas, United States, 66211